Overall, our data demonstrate that G-1 exerts potent anti-MM activity, even capable of overcoming the protective BM milieu, modulating an established miRNA-transcription factor loop, i.e., the miR-29b-Sp1, operative in MM. This evidence concerns the gene SP1 and Miyoshi myopathy.